GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Total Current Assets

Pentixapharm Holding AG (XTER:PTP) Total Current Assets : €13.08 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Pentixapharm Holding AG's total current assets for the quarter that ended in Jun. 2024 was €13.08 Mil.


Pentixapharm Holding AG Total Current Assets Historical Data

The historical data trend for Pentixapharm Holding AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG Total Current Assets Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Total Current Assets
2.56 3.85 18.71

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
Total Current Assets 2.56 3.85 - 18.71 13.08

Pentixapharm Holding AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Pentixapharm Holding AG's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Pentixapharm Holding AG's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Pentixapharm Holding AG  (XTER:PTP) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Pentixapharm Holding AG's Liquidation Value for the quarter that ended in Jun. 2024 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=12.449-22.722+0.75 * 0.28+0.5 * 0
=-10.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pentixapharm Holding AG Total Current Assets Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Pentixapharm Holding AG Business Description

Traded in Other Exchanges
Address
Robert-Rossle-Street 10, Berlin, DEU
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines